MODIFICATION
66 -- Questions and Answers relating to Joint Biological Agent Identification and Diagnostic Systems (JBAIDS) Synopsis
- Notice Date
- 3/22/2002
- Notice Type
- Modification
- Contracting Office
- US Army Space and Missile Defense Command, Deputy Commander, ATTN SMDC-CM-AP, P.O. Box 1500, Huntsville, AL 35807-3801
- ZIP Code
- 35807-3801
- Solicitation Number
- DASG60-02-R-0008
- Response Due
- 3/28/2002
- Archive Date
- 4/27/2002
- Point of Contact
- Warren Potter, 301-619-2383
- E-Mail Address
-
Email your questions to US Army Space and Missile Defense Command, Deputy Commander
(PotterW@smdc.army.mil)
- Small Business Set-Aside
- N/A
- Description
- NA The following questions and answers are provided for information only. They are not intended to change any of the requirements for offorer provided information in response to Phase 1 of subject Synopsis. Therefore, the Phase 1 Offeror Response date remai ns March 28, 2002. Question 1: What types of samples should be accepted/processed in the Block I and Block II systems? (liquid/air samples, environmental samples, medical samples, samples taken from surfaces, sample volume, etc.). Answer 1:The contractor's system needs to p rocess both clinical and environmental samples. Sample preparation should include procedures for collection from a variety of clinical and environmental specimens, with clinical samples focusing on (but not limited to) pharyngeal swabs, nasal swabs, and b lood, and environmental samples focusing on but not limited to aerosol (biodetector) buffer, (potable) water, food samples. Question 2: What level of sample preparation should be integrated in the Block I and Block II systems? What level of automation for the sample preparation? Answer 2: Automatic sample preparation is not a Block I or II threshold requirement. Question 3: Is there a list of BW agents which will be used in the Flyoff Test? Could we choose (4-6) BW agents for which we already fully developed the protocols and reagents? How complex sample matrices will be used in the Flyoff Test (number of agents, interfering species, volume, etc). Answer 3:The identity of the BW agents will be provided as a part of the Phase 3 purchase order package. Question 4: Will the samples in the Fly-off test contain pathogens or DNA only? What is the expected concentration range or detection limits for the offered JBAIDS system? Answer 4:Inactivated antigen preps will be given to all participants (suitable for both nucleic acid & protein based systems). Further information regarding sensitivities/limits of detection or identification will be provided as a part of the Phase 3 purchase order package Question 5: Will the development costs for the Block I and Block II systems be completely or partially covered? Answer 5: Costs prior to receipt of a Phase 3 purchase order are at the offeror?s own expense. The phase 3 purchase order will identify those costs that are eligible for compensation NTE $50,000. The phase 4 RFP will provide more information relating to the potential contract. Question 6: How important will be the cost of the Block I (or Block II) system in the evaluation of vendors? Answer 6:The phase 4 RFP will provide more information relating to the potential contract. Question 7: The solicitation mentions that potentially multiple awards will be made. What are the selection criteria and in what situation will multiple awards be made? Answer 7:The criteria that will be used to issue multiple purchase orders is that whic h is described in subject synopsis prior to the description of phase 3. In reference to phase 4, the synopsis indicates as follows: ?The Government may award more than one contract for the JBAIDS system.? The phase 4 RFP will also contain criteria for se lection. The Government reserves the right to award more than one contract for the JBAIDS system. Question 8: Is there an envisioned set-aside level of funding for this opportunity, and within what period of time? Answer 8:The Government has adequate funding for the potential phase 3 purchase orders. The amount of funding for the potential contract o r contracts for the JBAIDS requirements at phase 4 is to be determined. Question 9: We would like clarification about which of the 4-6 BW agents proposed for the flyoff testing and evaluation will be used? Answer 9: The identity of the BW agents will be provided as a part of the Phase 3 purchase order package. Question 10: We plan to obtain either through teaming or purchase, several interim platforms for the short term response. As the teaming agreement may not be concluded prior to submission of the pre-SOL, how should we proceed (list as to be concluded, separate item, etc?). Answer 10: The JBAIDS program is open to any technology that can meet the program requirements to identify DoD BW agents IAW JBAIDS ORD requirements. As stated in the Presolicitation Notice, the Go vernment is looking at mature technology for the Block I JBAIDS Diagnostic system due to requirements to start fielding systems to all four Military Services after a short, less than one year, development/demonstration period. Government program office re quirements for pre-screening of eligible offerors are noted in the Presolicitation Notice. All offerors that can meet the Government's stated requirements are welcome regardless of technology used. Question 11: Also, how detailed should the initial proposal be? Answer 11: It is recommend that you use the wording in the synopsis as your guide for preparing the documentation required by the synopsis. Question 12: It is our understanding DOD would like a system that can be fielded ASAP (is there a realistic expectation time frame) followed by next generation systems for a later time. Answer 12: Subject synopsis identifies the anticipated time frame for JBAIDS evolutionary block efforts. Question 13: Samples to be tested include: Human, environmental, water, food, other. Are these assumptions correct? Answer: Sample preparation should include procedures for collection from a variety of clinical and environmental specimens, with clinical s amples focusing on (but not limited to) pharyngeal swabs, nasal swabs, and blood, and environmental samples focusing on but not limited to aerosol (biodetector) buffer, (potable) water, food samples. Question 14: I am developing UV technologies which originated with NASA JPL. I believe it may offer an opportunity for reagent-less testing with faster detection times. Please advise if this technology would even be considered within your program. Answe r 14: The JBAIDS program is open to any technology that can meet the program requirements to identify DoD BW agents IAW JBAIDS ORD requirements. As stated in the Presolicitation Notice, the Government is looking at mature technology for the Block I JBAIDS Diagnostic system due to requirements to start fielding systems to all four Military Services after a short, less than one year, development/demonstration period. Government program office requirements for pre-screening of eligible offerors are noted in the Presolicitation Notice. All offerors that can meet the Government's stated requirements are welcome regardless of technology used. Question 15: Is there any size limit or font requirements, word or PDF? Answer 15: It is recommended that your response to Phase 1 be submitted as a Word document using a Font that is Arial with a Size that is 12.
- Place of Performance
- Address: US Army Space and Missile Defense Command, Deputy Commander ATTN SMDC-CM-AP, P.O. Box 1500 Huntsville AL
- Zip Code: 35807-3801
- Country: US
- Zip Code: 35807-3801
- Record
- SN00047276-W 20020324/020322213359 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |